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Abstract 
Microglia are the resident immune cells of the central nervous system. They have 
been found to play a major role in the development of different neurodegenerative 
diseases. In the case of Alzheimer’s disease, understanding microglial interactions with 
Aβ peptides, a major hallmark of the disease, could unveil potential therapeutic targets. 
In order to study this interaction, it is important to be able to replicate it in vitro. 
However, there is no current model for microglial cells in vitro.  
Primary cultures of rodent postnatal microglia are currently the most used in vitro 
model for microglial cells, as they are the simpler method to obtain large numbers of 
primary cells. Nevertheless, this study shows that postnatal microglia grown in vitro 
with granulocyte-macrophage colony-stimulating factor (GM-CSF) do not present the 
levels of expression of microglial signature markers (TMEM119, FCRLS, P2RY12, 
TREM2) found in adult microglia in vivo. This microglial signature was also 
downregulated in postnatal microglia compared to adult microglia. From 
immunostaining of tissue slices at postnatal day 3 (P3) it was shown that at least one of 
this characteristic microglial markers (P2RY12) was present in most of the neonatal 
microglial cells, although it had lower levels of expression than in adult cells.  
Together, these results show that postnatal microglia have an immature phenotype 
and that current culture conditions are not able to promote differentiation of these 
immature cells into an adult phenotype. For this reason, neonatal microglia are currently 
not a good model for microglial studies concerning diseases that affect the adult brain.  
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1. Motivation and objectives 
Motivation 
Microglial cells are the central nervous system (CNS) resident parenchymal 
immune cells, accounting for around 5-12% of the cells in the adult brain, with major 
roles during disease, development and homeostasis [1], [2]. They were first 
characterized by Pio Del Río Hortega in a series of paper published in 1919 [3], but it 
was not until the late 1980s when studies of microglia began to emerge in neuroscience 
journals [4], [5]. This interest in microglial cells appeared as neuroinflammation was 
discovered to be a key element in the progression of neurodegenerative diseases 
including but not limited to Alzheimer’s disease [6]–[8], Parkinson’s disease [9], and 
amyotrophic lateral sclerosis [10].  
In the case of Alzheimer’s disease, neuroinflammation caused by microglial cells 
has been found to be a key component in the development of the disease, although the 
exact role these cells play has not been fully elucidated yet. An important step in 
unveiling this role would be to understand the mechanisms by which microglial cells 
interact with Aβ peptides, one of the main hallmarks in Alzheimer’s disease. 
Understanding the pathways involved in this interaction could reveal new targets for 
potential therapies.  
In order to further this line of research, the first step would be to have a reliable in 
vitro microglial model in which to perform the preliminary studies before moving on to 
in vivo studies.  
Historically, the attainment of this reliable model has faced one major challenge: 
microglial characterization, and particularly, the differentiation between microglia and 
related cells, such as circulating macrophages. Until recently, microglia was 
distinguished from infiltrating macrophages based on their ramified morphology and 
flow cytometry surface expression markers, where macrophages are CD11b
+
CD45
high
 
and microglia are CD11b
+
CD45
med/low
 [11]. However, activated microglia also present 
the amoeboid morphology typical of macrophages and CD45 expression can be 
compromised in the disease state. Other markers typically used to identify microglial 
cells (Iba-1, CD68, F4/80) are expressed by macrophages too [12], [13].  
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In the last decade, the development of new techniques such as single cell RNA-
sequencing has allowed for the discovery of a new set of microglial signature genes 
(P2RY12, SALL1, FCRLS or TMEM119) that are differentially expressed in microglia, 
but not in other myeloid cells or other brain cells [14]–[18]. However, although the 
expression of these genes characterizes adult microglia in homeostasis, it is worth 
noting that the microglial phenotype is highly variable, and changes during 
development and in the disease state [19], so the expression of these genes may be 
regulated at different developmental stages or in the context of inflammation or 
neurodegeneration [20], [21].  
Possible approaches to the development of a reliable microglial model would be 
the use of cell lines, freshly isolated adult cells, primary cultures of postnatal microglia 
or induced pluripotent stem cells (iPSCs). These different approaches will be analyzed 
in more detail when describing in vitro microglial models in the Background section.  
In the case of cell lines, although they are able to yield high numbers of cells, the 
accuracy with which they model adult microglial cells is low [15] and their potential for 
improvement in this regard is limited. The opposite occurs with the use of freshly 
isolated microglial adult cells. This model allows for perfect replication of microglial 
adult cells and thus it is currently used for studies that require high accuracy; however, 
the protocol is complex and the number of cells obtained from each animal is limited, so 
it is not a viable long term solution. In the case of both iPSCs and primary cultures of 
postnatal microglia, these methods present potential to be used as models for adult 
microglia, as they combine the ability to yield high number of cells with the potential to 
develop a microglial adult phenotype.  
This project will focus on primary cultures of microglial cells as they are currently 
the most used microglial model and therefore it is critical to characterize whether this 
method is suitable for modeling microglial cells [22]–[24]. This model allows for rapid 
attainment of large quantities of primary cells [25], and has been used to study signal 
transduction pathways as well as to gain an understanding of the functional 
consequences of gene expression manipulation. Nevertheless, due to the discovery of 
the aforementioned new microglial signature the suitability of this model might need to 
be revisited, as it is unclear whether cells from these primary cultures express the 
microglial signature required for them to be a proper model to study adult microglia. 
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Therefore, the motivation of this project will be to characterize whether postnatal 
microglia is a good model for adult microglia, in order to understand if it could be used 
in further studies concerning the interactions with Aβ peptides in the context of 
Alzheimer’s disease.  
Objectives 
The number of microglial cells obtained from mouse brains is very low, so cell 
culture protocols are needed in order to ensure that enough cells are obtained for 
biochemical and drug testing studies.  
Postnatal microglia are often used as a model for adult microglial studies (i.e.: 
testing the response to Aβ peptides). Nonetheless, after the discovery of a characteristic 
microglial signature, it is important to understand whether the primary cultures of 
postnatal microglial cells currently used as models present this characteristic phenotype.  
Based on this general focus, the objectives of this project will be the following: 
1. To characterize the microglial signature expression in cells cultured following 
the protocol described by Marshall et al [22], as it was considered for a long time the 
standard protocol for microglial culture. Some studies have already been done for other 
culture protocols [15], where they found that the primary cells did not present this 
characteristic phenotype. 
The mRNAs analyzed will be P2RY12, TMEM119 and FCRLS as they are 
characteristic microglial markers and TREM2, as it is a risk factor for Alzheimer’s 
disease typically expressed by microglia in the brain [26].  
2. To characterize whether the original microglia extracted from postnatal day 3 
(P3) mice expresses this microglial signature (P2RY12, TMEM119, FCRLS, and 
TREM2). With this objective, it will be possible to know whether the original microglia 
extracted from postnatal day 3 (P3) mice was expressing these markers and had lost 
them in culture, as occurs when culturing adult microglia [27] or whether postnatal 
microglia never expressed those markers to begin with.  
3. Characterization of the microglial population in the P3 brain by 
immunohistochemistry. The project will study both the spatial distribution and 
morphology of these cells and their expression of the microglial marker P2RY12.  
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The legal framework and the socioeconomic impact of this project, including a 
detailed budget, can be found in section 5.  
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2. Background 
Microglia: brain resident macrophages 
Microglia are the innate immune cells of the central nervous system (CNS), and 
constitute a unique kind of tissue-resident macrophage due to their embryonic origin. 
They belong to the myeloid lineage, and they derive from myeloid progenitors in the 
extra-embryonic yolk sac, which arise before embryonic day 8 (E8) and colonize the 
brain by E9 in mice, before the formation of the blood brain barrier that will block the 
entrance of other immune cells formed in later stages of development [28], [29]. Brain 
border macrophages also derive from the same yolk sac hematopoietic progenitors, but 
microglia begins to express a differential phenotype when it enters the brain 
parenchyma and receives the environmental signals that are necessary for its 
differentiation [19].  The combination of their embryonic origin and the environmental 
cues received in the CNS are both necessary in order for microglial cells to maintain 
their identity [27].  
Unlike other tissue resident macrophages, microglia are self-maintained due to 
their ability to self-renew [29] and remain yolk sac derived through the entire 
development and adulthood, without contributions from the circulating hematopoietic 
precursors. However, whether this microglial self-maintenance during adulthood is due 
to a small set of progenitors or to the self-replication of the entire microglial population 
is still obscure [20] .  
Exceptionally, peripheral hematopoietic cells contribute to the microglial pool 
during pathology [30]. Studies have shown that circulating blood borne macrophages do 
not acquire the microglial phenotype, as macrophages engrafted in the CNS do not 
present the characteristic microglial signature [27], although they do adopt other 
microglial characteristics, like a more ramified morphology or longer lifespans [31].  
Microglia in the adult brain are highly motile in that they are constantly remodeling 
their branches, but with no soma translation (non-migratory) [32]. This branch 
remodeling occurs as microglia sense their environment, which changed the paradigm to 
describe inactive cells as “surveying” rather than “resting” [33].  
In general, microglia are able to change their phenotype rapidly in response to 
different developmental or contextual cues [34].   
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Microglia during development 
Different studies have shown that the adult microglial population is the result of 
proliferation of microglial precursors [35] in the developing brain up to postnatal day 14 
[16], [36]. The peak expression of proliferating microglia is seen between P6 and P9 in 
rats, and coincides with a period of high brain architecture formation, including 
dendritic growth, synapse formation and myelination [35]. This high levels of 
proliferation during the first stages of development may be driven by myeloid precursor 
cells (CD11b+ cells expressing the myeloid precursor marker ER-MP58) [36]. 
Microglia have been found to follow a step wise developmental program that 
comprises three different stages. The first stage could be described as “early microglia” 
and it is characterized by highly mobile precursors with a primitive amoeboid shape that 
overexpress cell cycle genes, important for the colonization of the brain parenchyma in 
the first stages of embryonic development [37]. After embryonic day 14 (E14.0) and 
until postnatal day 9 (P9) microglia mature to a so called “pre-microglia”, with 
expression of genes regarding synaptic pruning and other structural functions[28], [35]. 
The late stage, corresponding to adult microglia would be characterized by their 
immune function and in this stage cells present a highly ramified morphology, with 
small soma and long, thin branching (Fig 1).  
 
Fig 1. Different stages of microglial development [38]. Microglial differentiation is 
characterized by an increase in the number of cells and a tendency towards a more ramified 
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morphology, as their functions evolve from more structural roles during brain development to 
immune surveillance and responses during adulthood. Although microglia have been found to 
play a key role in the developmental biology of the brain, no studies currently exist to describe 
their motility and migration during this period [32]. 
Microglia have very different roles throughout the lifespan. In the developing 
brain, microglial cells have structural functions, and are essential for synaptic pruning, 
myelinogenesis, axon dynamics, cell genesis and survival, stimulation of 
vascularization, as well as cellular phagocytosis, as during the first postnatal week 
microglia are often found close to or engulfing apoptotic bodies [30], [32]. Due to this 
variety of functions, microglia is most diverse during early development, and becomes 
less heterogeneous in the homeostatic adult brain [19]. 
A characteristic population of microglial cells has been found in the neurogenic 
subventricular zone (SVZ) during early postnatal stages. Microglia had been shown to 
be a component in the adult neurogenic niches, controlling neural stem cells 
proliferation, but they are already present in this region at early stages. This population 
is characterized by a more amoeboid phenotype, with lower differentiation rates than 
other regions and higher cell numbers than other regions [39].  
Microglia have been proved to be heterogeneous along a temporal axis, with 
different functions at different life stages; however, the level of heterogeneity of 
microglia along a spatial axis, especially during development, remains unanswered [20]. 
It is clear that environmental cues drive the phenotypic expression in microglia, but 
what are these cues and how microglial cells are driven to change between the different 
functions is still unsolved.  
In vitro microglial models: iPSC, adult/neonatal primary cells and cell 
lines 
Biological models are systems used to increase the scientific understanding of a 
particular biologic phenomenon. For the case of microglial models, as most diseases 
develop during the adult age, they should aim to reproduce the adult phenotype under 
physiological state. In vitro models could be distinguished in four main groups: cell 
lines, primary microglia derived from mixed glial cultures, ex vivo adult microglia and 
stem cell-derived microglia cultures, including the use of induced pluripotent stem cells 
(iPSC).   
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Immortalized cell lines for microglia include HMC3 or HMO6 for human, BV2 
and N9 retroviral immortalized murine microglia, and spontaneously immortalized 
rodent microglial lines like EOC lines and HAPI cells [33]–[35]. Among these cell lines 
the most commonly used are the BV2 and N9 lines, due to the ease of use. The main 
advantage, common to all cell lines, is the ability to obtain high numbers of cells in 
short time spans without employing animals. However, although these cell lines present 
similar responses to different stimuli like LPS and Aβ, the magnitude of the responses is 
different [40], and recent studies have shown that they present differences in both 
genetic expression and function compared to ex vivo adult microglia [15], [41]. Besides, 
both BV2 and N9 are derived from neonatal microglia, meaning that any differences 
that were present between neonatal and adult primary microglia will also affect these 
cell lines.  
In the case of primary cells, the gold standard for microglia is currently freshly 
isolated adult microglia. These ex vivo cells present the advantage that they were 
differentiated in the CNS, and thus present the characteristic genotype and phenotype of 
microglia in vivo [25]. The reason why these cells are only used for characterization, but 
not for studies regarding biological responses or biochemistry testing is because the 
number of cells yielded by each experiment is extremely low, and any experimentation 
performed in this model would require the sacrifice of huge amount of animals.  
For this reason, primary cultures are used to optimize the amount of cells obtained. 
Cells are first grown in mixed glial cultures and then microglia is purified by density 
gradients, magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting 
(FACS) or by specific shaking procedures [16], [22], [36], [42]. The main drawbacks of 
this technique are the evolutionary differences between rodents and humans, that can 
hamper the translation of basic research results to the clinic, and also the possible 
differences between the neonatal microglia being cultured and adult microglia.  
To reduce the amount of animals employed while maintaining the biological 
relevance of primary cultures, the ideal model would be the use of stem-cell derived 
microglia, particularly iPSCs. However, to obtain any kind of cell from iPSCs it is vital 
to understand the key factors driving the developmental process and until 2010, even 
the origin of microglial cells was under debate [28]. In the last decade, different 
protocols have been described for the differentiation of iPSCs into microglial cells [43]–
[45], including different factors like M-CSF, IL-34, TGF-β1, or cholesterol, that have 
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been found to be relevant in microglial development [30]. However, these methods are 
able to obtain microglia-like cells presenting an immature phenotype resembling that of 
in vivo embryonic microglia, so conclusions reached using these cells should not be 
extrapolated to adult studies.  
As a summary, there is no current ideal model for studying microglia in vitro, as 
there is a lack of understanding of the environmental cues that are necessary for the 
differentiation and maintenance of the microglial phenotype. For this reason, in order to 
develop a useful model it is of the maximum importance to understand the biology of 
microglial development in vivo, in order to replicate the process in vitro.  
Microglial visualization in tissue samples 
The first drawings of the morphology of neuroglial cells in the early 20
th
 century 
were performed based on unstained tissue by histologists such as Camillo Golgi, 
Santiago Ramón y Cajal, and Pio Del Rio Hortega [46]. Throughout the next decades, 
different methods were developed in order to selectively stain only particular types of 
cells, including Cajal’s gold-chloride-sublimate staining, which allowed for the 
visualization of neuroglia. Later on, Rio Hortega was able to selectively stain microglia 
by using a modification of the ammoniacal silver staining method developed by 
Achúcarro [47].  
Nonetheless, these methods only allowed for morphological staining. It was in the 
late 1980s when immunohistochemical methods appeared and it was possible to stain 
cells based on their functionality, for example by staining brain samples with anti-F4/80 
antibodies, a macrophage specific antibody that was able to stain microglial cells, as 
well as other macrophages present in the CNS like those associated with the choroid 
plexus, ventricles and meninges [48].  
Current techniques for visualization of microglia in tissue samples still rely mainly 
on immunostaining, particularly of markers such as Iba1, CD45 or CD68. Other 
approaches include the use of transgenic animals, which express eGFP following the 
promoter for another gene. For the case of microglial cells, the most used transgenic 
animals are the CX3CR1-eGFP and the CSF1R-eGFP transgenic models. 
In order to facilitate the study of microglial cells in the brain, CSF1R-eGFP 
transgenic mice will be used in this project. CSF1R (Colony Stimulating Factor 1 
Receptor) is a receptor for CSF-1, also known as M-CSF, and interleukin-34 (IL-34) 
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and it plays an important role in regulating the proliferation, differentiation and function 
of macrophages [49], [50]. CSF1R is expressed by all the mononuclear phagocyte 
system from the myeloid lineage [51]. In the brain, it is expressed not only by 
microglia, but also by perivascular macrophages, and macrophages from the meninges 
and the choroidal plexus. In order to overcome this issue, some recent studies [16] have 
relied on the use of immunostaining with antibodies binding characteristic microglial 
markers like TMEM119 in order to specifically stain only microglial cells and no other 
myeloid cells. However, the expression of these markers is not guaranteed on different 
stages of development and thus it will not be used in this project as it deals with 
postnatal microglia. Nevertheless, as the rest of CSF1R-expressing cells are localized in 
very specific regions of the brain, they can be easily distinguished from CSF1R
+
 
microglia found in the brain parenchyma. For this reason, microglia will be 
characterized as eGFP
+
 cells found in the parenchyma of the brain. 
All the images of tissue sections acquired for this work were obtained using 
confocal microscopy. The section below details the reasons why this technique was 
used over standard fluorescence microscopy.  
Imaging: confocal microscopy vs standard fluorescence microscopy  
Both immunostaining and the use of transgenic animals require fluorescence 
microscopy in order to visualize cells. This section will describe why confocal 
microscopy was used for imaging brain tissue samples instead of standard fluorescence 
microscopy.  
Fluorescence is a form of energy emitted by some molecules (fluorochromes) when 
they are excited by light photons. Part of that excitation energy is lost in the form of 
heat, so the emitted fluorescence light always has less energy –and higher wavelength– 
than the original one. This physical property has been used for years in biological 
research with traditional fluorescence microscopes (Fig 2A). However, standard 
fluorescence microscopes present several disadvantages, including the overlapping 
between the excitation curves of different fluorochromes. As a practical example of this 
issue, eGFP is excited with blue light and emits in green, but it is also partially excited 
by green light and can emit in red, overlapping with the Cy3 emission in red. The other 
main disadvantage is that the light received at the detector not only comes from the 
focus plane, but also from all the other planes in the section. This can be particularly 
challenging in the case of imaging brain slices, as the brain has high autofluorescence 
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properties, particularly due to the accumulation of lipofuscins in the neural cells [52]. If 
the light captured comes from all the possible planes in a section, the unspecific 
fluorescence can mask the true signal from the eGFP protein of the transgenic model 
(Fig 2B).  
These disadvantages can be overcome using confocal microscopy. The main 
characteristic that differentiates confocal microscopy from other kinds of fluorescence 
imaging is that it detects only the light coming from a focal plane in the three 
dimensional space. The thickness of this focus plane can be controlled by changing the 
pinhole, an opening diaphragm that controls the amount of light that gets to the detector. 
Opening the pinhole allows for more fluorescence to come in, as it takes the light 
coming from more planes, increasing the signal; while closing the pinhole improves the 
z-resolution of the images and reduces the amount of nonspecific light that gets to the 
detector. 
The other problem solved by confocal microscopy is the overlap between the 
emissions of two fluorochromes. Confocal microscopy overcomes this challenge with 
two different solutions. For one, the excitation lights are lasers, which emit in only one 
wavelength, reducing the possibility of exciting two fluorochromes with the same one. 
Besides, confocal microscopy allows for sequential acquisition of the images. This 
means that the specimen is first excited with one laser, the light emitted is captured and 
then the next laser is switched on. With these two techniques, the overlapping between 
fluorescence is greatly reduced and becomes almost nonexistent.  
For these reasons, confocal microscopy will be used along this project in order to 
visualize microglial cells in tissue slices.  
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Fig 2. Comparative between standard fluorescence and confocal microscopy. (A) 
Schematics of a standard fluorescence microscope (Wikimedia Commons, modified)   (B) 
Schematics of a confocal microscope. Light emitted by fluorochromes outside the focal plane 
(dotted line) gets blocked by the pinhole, and only light coming from the focal plane (block 
line) gets to the detector [4]. (C) Hippocampus of a neonatal (P3) mice imaged using standard 
fluorescence microscopy with a 10x objective (Leica DM IL LED). All the tissue shows 
fluorescence, the specific fluorescence coming from the transgenic CSF1r-eGFP cells cannot be 
distinguished. (D) Hippocampus of a neonatal (P3) mice imaged using confocal microscopy 
(20×/0.7 Plan Apo objective lens, Leica SP5 MP). Confocal microscopy greatly reduces the 
intensity of nonspecific fluorescence.  
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3. Materials and methods 
Animals  
Primary cultures of mixed glial cells were obtained from Mus musculus C57BL/6 
neonatal (P2-P3) males and females. Animals employed included C57BL/6 wild type 
mice and mice from the FMS strain (B6.Cg-Tg(Csf1r-EGFP)1Hume/J),  which was first 
generated and characterized by Sasmono el at in 2003 [54], [55] (Fig 3). Animals were 
provided by Instituto de Salud Carlos III (ISCIII). Pregnant females were allowed to 
give birth naturally, and the day of birth was considered P0. Animals were kept housed 
with sterile food and water ad libitum in “specific-pathogen free” (SPF) conditions. 
 
Fig 3. CSF1R-eGFP transgenic. Schematic of the transgenic mouse used and map of the 
p7.2 fms -EGFP plasmid construct used for the transfection [55].  
Microglial extraction 
Animals were sacrificed by decapitation in a horizontal flow cabin to maintain 
sterility. For immunostaining, brains of pups were maintained in the skull to preserve 
their structural integrity. When brains were going to be used for cell culture, flow 
cytometry or RNA analysis, they were extracted from the skull and the olfactory bulbs, 
the cerebellum and the meninges and choroid plexus were removed to reduce 
contamination by external myeloid cells.  
Tissue disaggregation for cell culture and flow cytometry was performed following 
the protocol described by Marshall et al [22]. Brains were dissected and mechanically 
disaggregated with a 1000 µL pipette. The resulting mixture was filtered through a 70 
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µm cell strainer and pelleted by centrifugation at 1200 rpm for 5 min. Cell pellet was 
then retrieved for use in cell culture, flow cytometry or RNA analysis.  
When extracted cells were employed for the analysis of microglial markers by real 
time quantitative PCR (RT-qPCR), CD45+ cells were retrieved by magnetic cell 
isolation using a MACS cell separation kit (MACS Miltenyi Biotec). Isolated cells were 
stored at -20ºC until use.  
Cell culture 
Cell culture was performed following the protocol described by Marshall et al. [22] 
(Fig 4). Briefly, cells were extracted as described in the section above, and then seeded 
into 25 cm
2
 culture flasks in a neural growth medium (NGM) composed of Dulbecco’s 
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) with L-Glutamine and 
Penicillin/Streptomycin, supplemented with 5% FBS, recombinant human epidermal 
growth factor (EGF, 20ng/mL, PrepoTech), fibroblast growth factor (FGF, 10ng/mL, 
PrepoTech) and supplement N2 (Gibco). Cells were allowed to grow at 37ºC and 5% 
CO2 until a confluent monolayer was formed. Cell were then transferred to a 75 cm
2
 
flask with the same culture media composition and again allowed to reach confluency. 
Confluent cells were seeded again at a 1:3 ratio to three 75 cm
2
 flasks with microglial 
proliferation medium (MPM), which consisted of DMEM/F-12 supplemented with 10% 
FBS, N2 and granulocyte macrophage-colony stimulating factor (GM-CSF, 20ng/mL, 
PrepoTech).  
 
Fig 4. Culture protocol described by Marshall et al. [22]. From extracted brains, olfactory 
bulbs, cerebellum, meninges and choroidal plexus were removed. The tissue was mechanically 
disaggregated, filtered through a 70 µm cell strainer and seeded into cell culture flasks. Culture 
media used were neural growth medium (NGM): DMEM/F12 + 5%FBS + N2 supplement + 
EGF (20ng/mL) + FGF (10ng/mL) and microglial proliferation medium (MPM): DMEM/F12 + 
 19 
 
10% FBS +N2 supplement + GM-CSF. Cells were passaged when cell monolayers reached 
confluency.  
When cells reached confluency, they were retrieved for flow cytometry and RNA 
analysis. Microglial retrieval from mixed cell cultures was performed by agitation of the 
flasks at 150 rpm overnight.  
Characterization of cell surface marker expression: flow cytometry 
Flow cytometry was used to characterize cell populations both after extraction and 
after 14 days of culture. In flow cytometry, cells are stained using antibodies attached to 
different fluorophores. Each cell passes individually through the laser light and the light 
scatter and fluorescence emitted are electronically detected [56].  For this reason, this 
technique allows for very specific characterization of cell populations.   
A minimum of 50,000 cells were used for each tube. All incubations described 
below were performed in dark and cold conditions. Cells were first incubated with an 
anti-CD16/CD32 (BD Pharmingen
TM
) for 30 minutes to block the Fc region prior to 
incubation with antibodies for 45 minutes. The antibodies used were PE/Cy7 anti-
mouse CD45 (BD Pharmingen
TM
) and APC/Cy7 anti-mouse CD11b (BD 
Pharmingen
TM
).  
After incubation, 3 mL of PBS with 2% FBS were used to stop the reaction. Cell 
suspensions were centrifuged at 1200 rpm for 10 minutes and left in 500 µL of PBS 2% 
FBS. Cells were then passed through the cytometer (BD LSRFortessa
TM
 X-20) and the 
results analyzed using the FlowJo V10.1 software (Fig 5). 
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Fig 5. Representative figure of the selection criteria used during flow cytometry analysis. 
SSC-A/FSC-A was used to select the original population based on size and granularity. FSC-
W/FSC-H and SSC-W/SSC-H were used to remove duplets and purify the population. DAPI 
staining was used to select only the living cells, as dead cells could have a compromised 
membrane and thus present non-reliable staining.  
Characterization of mRNA expression: qRT-PCR 
To study the expression of different microglial markers at RNA level, a 
quantitative RT-PCR was performed.  
First, RNA was extracted with TriPure Isolation Reagent from frozen cell pellet 
samples following the phenol-chloroform standard protocol [57]. 1 mL of TriPure 
Isolation Reagent was added to pelleted cells in order to break them and denaturalize 
endogenous nucleases, preserving the integrity of nucleic acids. Samples were lysed 
using the embolus of a 5 mL syringe. Then the lysate was collected and incubated in a 
1.5 mL Eppendorf for 5 min at room temperature.   
After incubation, 200 µL of chloroform were added (1:5 proportion to TriPure) and 
mixed by vortex for 15 s to ensure proper mixture. After addition of chloroform, lysates 
were centrifuged (12,000 g, 15 min, 4ºC) to separate the phases. RNA is in the 
transparent aqueous phase, DNA in the interphase and proteins and other molecules in 
the organic phase below. Aqueous phase was extracted and transferred to a new 
Eppendorf with 500 µL of isopropyl alcohol (1:2 proportion to TriPure) to precipitate 
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isolated RNA. Tubes were inverted and incubated for 10 min at room temperature. 
Samples were centrifuged (12000g, 10 min, 4ºC), and then the pellet was resuspended 
in 200 µL of ethanol 75% to wash RNA samples. Samples were centrifuged again (7500 
g, 5 min, 4ºC), and RNA pellet was left to dry at room temperature.  
Once RNA was isolated, samples were resuspended in 12 µL of nuclease-free 
water (Gibco
®
). Samples were incubated for 7 min at 60ºC and RNA concentration 
measured using a Nanodrop (Nanophotometre Pearl, IMPLEN, bioNova cientifica), 
which quantifies RNA concentration using spectrophotometry principles.   
When the number of cells in a sample was below 250.000 the RNeasy Micro Kit 
(QIAGEN) was used, according to the prescribed protocol.  
As qRT-PCR is used to quantify relative amounts of DNA in a sample, to quantify 
the amount of RNA retrotranscription was used to obtain the complementary DNA 
(cDNA). Quantifying cDNA is homologous to quantifying RNA as during 
retrotranscription only one cDNA is obtained for each RNA molecule.  
cDNA was synthesized from isolated RNA samples. RNA samples were diluted to 
2 or 1 µg/µL in nuclease-free water, depending on the amount of RNA present in each 
sample, for a final volume of 10 µL. Diluted samples were converted to cDNA by 
retrotranscription. To each 10 µL sample, the following mixtures were added according 
to RT-PCR cycles:  
-Mixture 1 (2 µL/10 µL sample) contained 0.2 µL of random primers (Invitrogen, 3 
µg/µL 58875), 1 µL of DNTPs and 0.8 µL of nuclease-free water.  
-Mixture 2 (7 µL/10 µL sample) contained 4 µL of Strand buffer (Invitrogen,  
y02321), 2 µL of DTT, 0.1 µL of the recombinant ribonuclease inhibitor RNAsa 
OutTM (40U/µl, Invitrogen, 100000840)  and 0.9 µL of nuclease-free water. 
-1 µL of MMLV enzyme. 
Samples of cDNA obtained were diluted to 2 ng/µL in nuclease-free water. RT-
qPCR (QuantStudio 3, Applied Biosystem) was performed following the SYBR Green 
protocol, with two technical replica of each biological replica. mRNAs analyzed were 
36B4, as a housekeeping gene for control, and the characteristic microglial genes 
TMEM119, FCRLS, TREM2 and P2RY12 (Table I).  
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Table I. Primer sequences used for real time quantitative PCR (RT-qPCR). 
Gene Forward sequence  Reverse sequence 
36B4 5’-AGATGCAGCAGATCCGCAT 5’-GTTCTTGCCCATCAGCACC 
TMEM119 5’-GCATGAAGAAGGCCTGGAC 5’-CTGGGTAGCAGCCAGAATGT 
FCRLS 5’-GCCTTTGATTGTGGACATGA 5’-GATCTTCAGAAAGTGCTGGTAA 
TREM2 5’-TGGGACCTCTCCAACCAGTT 5’-GTGGTGTTGAGGGCTTGG 
P2RY12 5’-CCCGGAGACACTCATATCCTT 5’-GTCCCAGGGGAGAAGGTG 
 
Brain collection and sucrose cryoprotected tissue freezing 
Isolated brains used for immunohistochemistry were fixed overnight in 4% PFA. 
The skulls were conserved to preserve tissue integrity. Brains were washed with PB1x 6 
times for 10 minutes each in agitation and placed in 15% sucrose in PBS until they sank 
(12-24h) and then in 30% sucrose in PBS overnight or until they sank. This sucrose 
gradient was performed to avoid the formation of crystal due to the freezing of water 
inside the tissues. Brains were embedded in O.C.T. (Tissue-Tek O.C.T™, Sakura) and 
PB1x sucrose 30% solutions, at 1:3, 1:1 and 3:1 ratios successively, leaving them on 
each solution overnight.  
For tissue freezing, each brain was introduced in the bulb of a 3 mL Pasteur pipette 
filled with O.C.T., vertically oriented, with the olfactory bulbs facing downwards. Bulbs 
were progressively introduced in an Iso-Pentane (VWR Chemicals) beaker at -80ºC, 
until every part but a small circle of O.C.T. was frozen. Bulbs were transferred to dry 
iced and allowed to fully freeze. Frozen brains were stored at -80ºC until sectioning was 
performed.  
Cryostat sectioning and immunostaining  
Once brains were embedded in O.C.T, they were coronally sectioned using a 
cryostat CM1950 (Leica Microsystems) following the protocol described by Diaz-
Moreno in 2013 [58] generating 30 µm sections that were collected in Superfrost Ultra 
Plus® microscope slides (Thermo Fisher). Slides were kept at -20ºC until use.   
As brains came from FMS mice, they inherently expressed eGFP in myeloid cells 
(when CSF1-R is expressed). Immunofluorescent staining was performed using indirect 
standard staining: samples were first incubated with a primary antibody, followed by 
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incubation with a secondary fluorescent antibody. All the incubations were performed 
in darkness to preserve fluorescence.  
Samples were allowed to dry for two hours to avoid detachment from the slides 
prior to incubation in a blocking solution (0.1M PB, 10%FBS (Hyclone), 0.25% Triton-
X100 (Sigma-Aldrich), 150mM glycine (Merck)) for 1 hour. Samples were 
subsequently incubated overnight at 4ºC with the primary antibodies made in the 
blocking solution. Rabbit anti-P2RY12 (Anaspec) and rabbit anti-GFAP (Z033429, 
Dako) antibodies were used.  
The antibody solution was decanted and samples washed 3 times with PB. Then 
they were incubated with secondary antibodies for one hour. The secondary antibodies 
used were Alexa Fluor 647 donkey anti-rabbit (Dako) and Cy3 goat anti-rabbit (Dako). 
All incubations were performed in a wet chamber at room temperature in the dark, 
unless otherwise stated.  
To better visualize the anatomy of the sections in the confocal microscope, samples 
were stained with DAPI (4′,6-diamidino-2-phenylindole). DAPI is a fluorescent stain 
that binds adenine-thymine regions of the DNA, effectively staining the nucleus of 
eukaryotic cells. At normal concentrations, it can only pass through the membrane of 
compromised cells and that is why it is used to discriminate between living and dead 
cells in flow cytometry, for example. However, as cells in tissue slides are fixed and 
thus their membranes compromised, DAPI can stain all nuclei and be used to see a 
general anatomical structure of the tissue samples. After washing the secondary 
antibody, sections were incubated for 10 minutes with DAPI. DAPI was rinsed with PB, 
and then slides mounted using Mowiol/DABCO 2.5% (v/v) mounting solution. 
Imaging of tissue sections with confocal microscopy 
Fluorescence images were captures using a Leica SP5 MP confocal imaging 
system. For confocal imaging of samples, the following laser lines were used: DAPI 
(405 nm Diode), eGFP (Argon 488 nm), Cy3 (HeNe 543 nm) and Alexa Fluor 647 
(HeNe 633 nm). A sequential mode of acquisition was used to capture images to avoid 
cross excitation of the fluorophores. The confocal pinhole was set to one Airy disc unit 
to improve the z-resolution of the images and reduce the nonspecific fluorescence. To 
capture large fields of view (775 µm x 775 µm) images were collected using a 20×/0.7 
Plan Apo objective lens, with an x-y resolution of 1.3 pixels/µm and a typical z-
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resolution of 2.7 µm. For morphological imaging of single cells, a 63x/1.4-0.6 Plan Apo 
objective lens was used, giving an x-y resolution of 4.2 pixels/µm. Z-resolution was 
typically set between 0.3 and 0.7 µm.  
Image stacks obtained were processed using the Leica LAS AF software or ImageJ 
(Wayne Rasband, NIH). A median filter in 3D was applied to image stacks to reduce 
impulse noise and then image stacks were projected with a maximum projection to 
obtain a two-dimensional visualization of the region.  
Statistical Analysis 
Results are expressed as mean ± SD, n values reported for each experiment. Raw 
data was analyzed using Prism (GraphPad Software, Inc.). Data sets were tested for 
normality with a Saphiro-Wilk test. For normal distributions of data, significant 
differences were tested using one-way ANOVA with Brown-Forsythe correction. 
Kruskal-Wallis test was used for non-normal distributions of data. Unpaired t-test with 
Welch’s correction was used for comparison between two datasets.  P values below 0.05 
were considered significant. 
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4. Results 
Microglial tracing using the CSF1R-eGFP transgenic mice  
The use of transgenic mice as the CSF1R-eGFP is of great help to easily localize 
cells of interest, both in tissue preparations and in mixed cell cultures, where cells are 
growing alongside other cell types (as astrocytes or oligodendrocytes, in the case of 
mixed glial cultures). To ensure that eGFP expressing cells were indeed the population 
of interest, freshly isolated cells from postnatal brains (P3) were analyzed by flow 
cytometry. The markers analyzed were CD45 and CD11b, as microglial cells were 
classically characterized as being CD11b
+
 CD45
me
 [11]. eGFP
+
 cells were CD45
+
 and 
CD11b
+
 (Fig 6) ensuring that the population of interest is being correctly followed using 
this transgenic.  
The fact that eGFP
+
 cells are CD45
+
 and CD11b
+
 does not imply that they are 
necessarily microglial cells, as other cell types also express these markers. However, as 
cell cultures were only made with the brain parenchyma and removing the olfactory 
bulbs, the meninges and the choroid plexuses (which could be the main source of 
macrophages and other myeloid cell types) it was considered for the purpose of this 
work that the majority of myeloid cells present in the cell mixture will be microglial 
cells. 
 
Fig 6. Percentage of eGFP+ cells obtained from whole brain extractions of neonatal 
CSF1r-eGFP mice. (A) Cytometry protocol followed. (B) Flow cytometry analysis of the 
eGFP+ cells among living cells. Population was selected as described in Fig 5. All eGFP+ cells 
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were CD45+ and CD11b+. (C) Percentage of eGFP+ cells obtained from neonatal brains 
compared to the same percentage obtained from 3-4 months adult mice (n=6). **** P<0.0001.  
It is also important to notice that, as found in the literature [35], [36], the number of 
microglial cells is significantly lower in the neonatal brain compared to the brain of 
adult mice of 3 to 4 months, as microglial expansion occurs around day 14 of postnatal 
life in the murine brain [36]. This is one of the main reasons why cell cultures are a 
required step in any study that employs primary neonatal microglia, as obtaining the 
amount of cells needed for any experimental set up would require the sacrifice of big 
numbers of animals, violating the ethical guidelines that advocate for an optimization of 
the amount of animals employed for experimental research.  
Microglial signature expression in cultures with GM-CSF  
As stated in the previous section, a necessary step for microglial models is cell 
culture to increase the amount of cells available. In the culture protocol followed, the 
first step includes culture in neural growth medium (NGM) that enhances the growth of 
an astrocytic layer, and then cells are cultured in a microglial proliferation medium 
(MPM) that includes GM-CSF, a cytokine that stimulates macrophage proliferation 
[59]. MPM medium was successful in increasing the number of eGFP
+
 cell in the 
cultures (Fig 7B and 7C). After culture, eGFP
+
 cells were collected by agitation, taking 
advantage of the fact that they grow in a semi adherent fashion on top of the astrocytic 
layer.  
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Fig 7. Mixed glial cultures following the Marshall et al protocol [22]. (A) Schematics of 
the culture protocol. (B) Representative fluorescence fields and the corresponding bright fields 
of cell cultures after 4 days in NGM. eGFP
+
 cells grow over a basal layer of astrocytic cells. (C) 
Representative bright field and fluorescence fields of cell cultures after 14 days in culture (7 
days in NGM and 7 days in MPM).   
By flow cytometry, it was shown that 98.95±0.9% of cells detached by agitation 
were eGFP
+
, and maintained the CD11b
+
 CD45
+
 expression (Fig 8A). However, qRT-
PCR analysis revealed that these cells had very low expression of the microglial 
signature genes (P2RY12, FCRLS, TMEM119, TREM2) compared to the levels 
expressed by freshly isolated adult microglial cells (Fig 8B). These results match what 
has been reported in the literature for other cell culture protocols [15], where levels of 
expression of the microglial signature decay after culture, as microglial cells have been 
shown to require the environmental cues present in the central nervous system in order 
to maintain their characteristic phenotype, and rapidly loose it when extracted from it 
[27].  
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Fig 8. Characterization of the microglial population obtained by agitation after 14 days of 
culture. (A) Characterization by flow cytometry. 98.95±0.9% of detached cells are eGFP
+
, 
meaning that agitation is a good method to obtain purified myeloid cells from mixed brain 
cultures. Detached cells maintain their myeloid characterization (CD45
+
, CD11b
+
). (B) 
Microglial signature expression in neonatal microglial cells after 14 days in culture (n=3) 
compared with the expression levels of microglia from adult mice of 3-4 months freshly isolated 
from the brain (n=1). * P<0.05. 
Microglial signature expression in neonatal (P3) microglial cells  
As microglial cells obtained from neonatal primary cultures do not express the 
characteristic microglial expression markers (P2RY12, TMEM119, FCRLS, TREM2), a 
question arises: did microglial cells lose their signature due to being in a cell culture 
environment different from their in vivo environment, or are these levels of expression 
normal for neonatal microglia?  
To answer this question, expression of the same set of microglial markers was 
analyzed in freshly isolated microglial cells from neonatal (P3) brains. CD45
+
 cells 
were isolated by MACS sorting and analyzed by qRT-PCR. Analysis of mRNA 
expression of these genes revealed low levels of expression of these markers in the 
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neonatal brain compared to the levels observed in the adult brain (Fig 9). Levels of 
expression of P2RY12 are expected to be low in the brains of P3 mice, with a steady 
growth up to a peak of expression at 4 months [15], [60]. In the case of Tmem119, 
although expression is expected to appear between P3 and P6, adult levels are not 
reached until postnatal day 14 [16]. FCRLS expression at P3 has been reported to be 
higher than for other markers [15], without reaching adult levels of expression.   
 
Fig 9. Microglial signature expression in P3 microglial cells. (A) Schematics of the 
neonatal microglial extraction protocol. CD45
+ 
cells were isolated from P3 brains (n=3) and 
analyzed by qRT-PCR. (B) Levels of expression are shown in comparison with expression 
levels of microglia from adult mice of 3-4 months freshly isolated from the brain (n=1). P-
values are shown for each graph. No significance levels were obtained due to the low number of 
adult samples analyzed.  
Overall, these results confirm what has been reported in the literature about 
microglial marker expression in postnatal brains using RNA studies. However, in order 
to fully characterize the microglial population at any stage, RNA expression is not a 
complete enough descriptor, as it misses the possible heterogeneity between microglial 
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populations of different brain regions. This heterogeneity in the population could mask 
the possibility that some cells have high levels of expression of these microglial 
markers, while others have no expression of it. 
To unveil these possible differences, the next step of the study will be to analyze 
the spatial distribution of eGFP
+
 cells in the microglial postnatal brain, and whether 
these cells are expressing the microglial marker P2RY12.   
CSFR1-R+ cells in the neonatal murine brain: spatial distribution and 
P2RY12 expression 
Microglial cells constitute between 5-12% of the cells in the adult rodent brain [2]. 
They are present in all the brain structures and have a highly ramified morphology, 
presenting a small cell soma with numerous long prolongations, which are vital for 
surveillance of their environment (FIG 10C). In the case of the postnatal brain, the 
distribution is highly heterogeneous (Fig 10B), and cells present a primitive ramified 
morphology (Fig 10D).  
 
Fig 10. Comparison between microglia in the adult and postnatal brain. Comparison 
between the hippocampus of an adult (A) and a P3 (B) CSF1R-eGFP transgenic mice. The 
differences in the number of cells between both stages are evident. These differences are not 
only apparent in the number of cells but also in the phenotype of the typical cells in the adult 
brain (C) and in the postnatal brain (D), where adult cells present smaller somas and longer, 
thinner ramifications. Images from adult brains belong to the doctoral thesis of Elena Quintana 
from the Neuroinflammation unit of Instituto de Salud Carlos III [61]. 
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The use of CSF1R-eGFP transgenic mice allows for a simple observation of 
microglial cells in the brain. There are also non-microglial cells expressing CSF1R in 
the brain, as meningeal macrophages and macrophages in the choroidal plexus, 
however, they are characteristically localized so they will not pose a problem for 
differentiation with the microglial population.  
Four main regions will be analyzed in this study, the hippocampus, the cortex, the 
striatum and the region surrounding the lateral ventricles which includes the neurogenic 
subventricular zone (SVZ). In these regions, the number of eGFP+ cells will be 
analyzed, as well as the number of cells expressing P2RY12, to be able to characterize 
the microglial population at P3, as a starting point to understand its suitability as a 
model for adult microglial studies.  
Description of the spatial distribution of microglial cells in the postnatal murine 
brain following the CSF1R-eGFP transgenic model  
Regarding spatial distribution, microglial cells are much more heterogeneously 
distributed in the neonatal brain compared to the adult brain. The concentration of cells 
is lower in all regions, particularly in the cortex (Fig 12A). Cells in the striatum (Fig 
13), in the cortex (Fig 12B) and in the hippocampus (Fig 11B) present a more ramified 
morphology, while cells close to the ventricles present a more amoeboid morphology 
(Fig 14).  These results match results published in the literature observed for rat models 
[35], [62] and partial observations for murine models using the CX3CR1-eGFP 
transgenic model [16], [63]. It is worth noting the existence of a region with a very high 
number of eGFP
+
 cells below the hippocampus (Fig 11C). These cells are disposed in 
what will be called “hippocampal stream” for simplicity, although the term is imprecise 
as there are no observations of mobility or migration along that axis. Cells in this region 
present a highly amoeboid morphology, similar to that in the ventricular region.  
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Fig 11. Microglial cells in the postnatal hippocampus. (A) 30 µm sections of the neonatal 
hippocampus, showing the location of CSF1R
+
 cells (green), showing an unevenly distribution. 
Hematoxylin/Eosin staining from the Allen Brain Atlas (P4 NISSL coronal, positions 303 and 
297) [64]. (B) Morphology of the cells inside the hippocampus. Cells show primitive ramified 
morphology, an intermediate morphology characteristic of developing microglial cells [62].  (C) 
Characteristic morphology of cells in the “hippocampal stream”, more amoeboid than cells in 
the surrounding regions.  
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Fig 12. Microglial cells in the postnatal cortex. (A) 30 µm sections of the neonatal cortex, 
showing the location of CSF1R
+
 cells (green). Cells are evenly distributed through the cortex, 
with a high concentration of eGFP expressing cells in the outer meninges, corresponding to the 
meningeal macrophages.  Hematoxylin/Eosin staining from the Allen Brain Atlas (P4 NISSL 
coronal, position 342) [64]. (B) Morphology of the cells in the cortex. Cells present a higher 
ramification degree than cells present in other structures, which could indicate later stages of 
development.  
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Fig 13. Microglial cells in the postnatal striatum. 30 µm sections of the neonatal striatum, 
showing the location of CSF1R
+
 cells (green). Hematoxylin/Eosin staining from the Allen Brain 
Atlas (P4 NISSL coronal, position 342) [64]. Representative morphology of the cells in the 
striatum.  
 
Fig 14. Microglial cells surrounding the lateral ventricles. 30 µm sections of the neonatal 
ventricles, showing the location of CSF1R
+
 cells (green). Some of the CSF1R+ are inside the 
ventricles, as the choroid plexuses are the interface between the blood and the cerebrospinal 
fluid and thus contain blood immune cells [65]. Hematoxylin/Eosin staining from the Allen 
Brain Atlas (P4 NISSL coronal, position 342) [64]. Representative morphology of the cells in 
the regions surrounding the ventricles.  
P2RY12 differential expression in the postnatal murine brain 
Once microglial spatial distribution had been characterized for the CSF1R-eGFP 
transgenic brain, the next objective was to study whether these eGFP
+
 cells expressed 
the microglial marker P2RY12.  
Contrary to what could have been expected by the low levels of mRNA expression 
found in these cells (Fig 9), the majority of cells expressed this surface marker in all the 
regions observed (Fig 15, Fig 16, Fig 17). It is worth noting that although not all the 
eGFP
+
 cells were P2RY12, all P2RY12
+
 cells were eGFP
+
, as could be expected. 
However, in some cases the level of fluorescence of the eGFP
+
 cells was very low, 
especially in the cells expressing P2RY12 (Fig 15B).  Also, as the eGFP protein is 
expressed in the cytoplasm of the cell, while the P2RY12 is a marker found in the 
surface of the cell, the intensity of the eGFP signal was higher in the soma of the cell, as 
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the majority of the cytoplasm volume is in that region, while the P2RY12 signal was 
distributed along the surface, which enhanced the visualization of the microglial 
processes (Fig 17B). It is worth noting that indeed P2RY12 was only expressed in the 
microglial cells and not in the meningeal macrophages (Fig 17A) or in the cells inside 
the choroid plexus (Fig 19). 
 
Fig 15. P2RY12 expression in the postnatal hippocampus. (A) eGFP+ cells in the 
hippocampus mostly expressed P2RY12 in their surface membrane, with the main exception of 
the cells found in the “hippocampal stream”. Hematoxylin/Eosin staining from the Allen Brain 
Atlas (P4 NISSL coronal, positions 303) [60]. (B) Representative eGFP+ cells in the 
hippocampal parenchyma. Cells expressing the P2RY12 marker show a more ramified 
morphology (left) than cells that do not express this marker (right).  
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Fig 16. P2RY12 expression in the postnatal striatum. (A) eGFP
+
 cells in the striatum 
mostly express P2RY12 in their surface membrane, with some exceptions. As occurred in the 
hippocampus, it appears as if the cells that do not express P2RY12 (right) have a higher 
intensity in the eGFP signal than the cells that do express P2RY12 (right).  Hematoxylin/Eosin 
staining from the Allen Brain Atlas (P4 NISSL coronal, positions 342) [60].  (B) Representative 
eGFP
+ 
P2RY12
+
 cells in the striatum.  
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Fig 17. P2RY12 expression in the postnatal cortex. (A) All eGFP
+
 cells in the cortex 
express P2RY12 in their surface membrane and present a primitive ramified morphology. 
Hematoxylin/Eosin staining from the Allen Brain Atlas (P4 NISSL coronal, positions 342) [60].  
(B) Representative eGFP
+ 
P2RY12
+
 cell in the cortex. It can be appreciated how eGFP 
expression is mostly found in the soma of the cells, while P2RY12 is found in the surface of the 
cell.  
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Fig 18. P2RY12 in the area surrounding the lateral ventricles. (A) general view and close 
up of the eGFP
+
 cells in the lateral ventricles region. Hematoxylin/Eosin staining from the Allen 
Brain Atlas (P4 NISSL coronal, positions 342) [60]. (B) Cells in the lining of the ventricles 
show a primitive ramified morphology and P2RY12 expression. 
 
Fig 19. P2RY12 expression in the interior of the ventricles. (A) eGFP+ cells in the interior 
of the third ventricle below the hippocampus are negative for P2RY12 staining, while microglia 
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in the brain parenchyma are P2RY12+. The same applies for other ventricular regions (B). 
Hematoxylin/Eosin staining from the Allen Brain Atlas (P4 NISSL coronal, positions 280) [60].   
Considering the “stream” found below the hippocampus, the cells had been found 
to present a more amoeboid morphology than other cells in the surrounding regions. 
These cells also lack the P2RY12 staining that was present in other cells of the 
hippocampus (Fig 20), which may lead to believe that they could be a different 
microglial population.  
 
Fig 20. P2RY12 expression in the “hippocampal stream”. eGFP+ cells in the stream present 
a more amoeboid morphology, and are also P2RY12
-
. As occurred with P2RY12
- 
in other 
regions, these cells present a higher eGFP fluorescence level than the surrounding eGFP
+
 
P2RY12
+
 cells. Hematoxylin/Eosin staining from the Allen Brain Atlas (P4 NISSL coronal, 
positions 280) [60].   
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5. Discussion 
The first objective of this project was to characterize the expression of microglial 
markers in the cells obtained following the Marshall et al protocol [22]. Several studies 
had found that primary cultures of microglial cells express lower levels of the recently 
characterized microglial signature [15], [16] compared to adult microglial cells. This 
first goal was achieved, and the study showed that the lack of microglial signature in 
primary cultures remains true for the Marshall et al protocol [22], so cells obtained 
using this procedure should not be considered models of adult microglial cells, 
particularly for studies that are testing the response to neurodegenerative signals such as 
the Aβ peptides found in Alzheimer’s disease, as the cells are phenotypically different 
from adult microglial cells. Although studies using these cell cultures can still provide 
useful insights, it is important to report that the conclusions reached may not hold true 
for adult microglial cells, as they present different phenotypes and are likely to respond 
differently to the same stimuli.    
Nevertheless, the fact that cells obtained from these mixed glial cultures do not 
show adult levels of expression of the microglial signature genes does not imply that the 
cells are not microglial cells, but only that they are not phenotypically adult microglial 
cells. In fact, in consonance with the second objective of this project, postnatal 
microglial cells were also found to present lower values of the microglial signature 
expression when compared to the adult microglia (Fig 9).  
For this reason, it is not possible to conclude whether the cells obtained following 
the aforementioned protocol are immature microglial or blood-derived monocytes and 
macrophages. The fact that they present low levels of the microglial markers could be a 
consequence of the immaturity of the cells also found in the freshly extracted postnatal 
microglia, combined with the fact that the culture protocol was unable to induce 
maturation in the cells in the same way the innate CNS environment would, probably 
because GM-CSF is not the most suitable cytokine for this purpose. Indeed, although 
some authors use this cytokine in their protocols [43], [66],other papers have tried using 
other cytokines as M-CSF or IL34 that are also ligands for the CSF1R (necessary for the 
formation and maturation of microglial cells [50], [67], [68]), but that are naturally 
present in the CNS. 
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In order to determine if these cells are indeed postnatal microglial cells and could 
be used as models for postnatal microglia, it would be necessary to find a set of genes 
that are characteristically expressed in postnatal microglia and study their expression in 
the different microglial culture protocols. In any case, what becomes apparent from 
these results is that postnatal microglial cultures are not reliable models for adult 
microglia.  
Overall, the first and second objectives of this project were achieved, as both 
primary cultures and neonatal microglia have been characterized.  
From these results, and knowing that the best options for microglial models in vitro 
would be postnatal microglial cultures or, ideally, the differentiation of iPSCs into 
microglial cells, understanding the microglial developmental process in vivo appears as 
a necessary step in order to replicate this process in vitro. 
As a first approximation for any attempt to reproduce this developmental process 
the first step would be to characterize the original population. For this reason, the third 
objective of this work was to describe the microglial population at postnatal day 3 (P3), 
both their spatial distribution and the expression of the microglial signature marker 
P2RY12. 
Considering the spatial distribution, it is remarkable that some eGFP
+
 cells were 
concentrated in a “hippocampal stream” below the hippocampus, and that these cells 
showed a more amoeboid morphology than cells from other regions. Immunostaining 
also showed that these cells were mainly P2RY12
-
, as opposed to other cells in the 
surrounding regions.  
These cells present a similar morphology and expression to the eGFP
+
 cells found 
in the subventricular zone (SVZ) (Fig 14). In a 2015 study, Xavier et al [39] 
characterized postnatal microglia in the neurogenic SVZ as being a copious population 
that outnumbered other region microglia during early postnatal stages. They also found 
that these cells were less proliferative and showed a delayed maturation compared to 
cortical microglia. The high number of cells and the fact that they present a more 
immature morphology compared to cells in the surrounding regions could lead to 
hypothesize that cells in the “hippocampal stream” are a similar population to the cells 
found in the SVZ. In that case, the “hippocampal stream” could be close to the 
subgranular layer of the hippocampus dentate gyrus, another neurogenic region. In order 
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to test this hypothesis, it would be interesting to analyze whether cells in the 
surroundings express Nestin, Sox2 or any other marker of neural progenitors [69].  
Another hypothesis for the origin of this “hippocampal stream” can be found in a 
study by Mercier et al. in 2012. In this study, the authors describe a meningeal 
projection below the hippocampus, continuous with the choroid plexus stroma [70], that 
would match what this study was describing as “hippocampal stream”. The authors of 
this paper characterized an N-sulfated HS neurogenic niche comprised as a single 
anatomical system that was formed by the olfactory bulb, the rostral migratory stream, 
the subventricular zone, the sub-callosum and subcapsule zones and that appeared to 
continue to sub-cortical meninges that connected with the hippocampal neurogenic 
zone. A follow up study found that these meninges found below the hippocampus were 
associated with Nestin
+
 neural progenitors  [71]. The main limitation to describing these 
cells as belonging to a meningeal projection would be that this “hippocampal stream”, 
to the best of our knowledge, is not found in the adult brain, and meninges are 
anatomical structures that are present throughout the lifespan without major changes.   
Nevertheless, the results obtained in this project are not sufficient to adventure a 
hypothesis about the origin and nature of these cells, and further research into their 
ontogeny and phenotype would be needed in order to determine whether these cells are 
microglial cells part of a stem cell niche, meningeal macrophages belonging to a 
meningeal projection or if they are involved in a completely different function that is yet 
to be discovered.  
Broadening the focus to microglial cells found in the other regions of the brain, it 
was found that microglial cells at P3 showed the phenotype that had been previously 
described as primitive ramified microglia [35], where they show a bigger cell soma and 
a limited number of processes that are shorter than the ramifications found in the adult 
brain. Besides, the number of cells is lower than in the adult brain, with cells distributed 
non-homogeneously among the different regions.  
Regarding the expression of P2RY12, it would have been expected that most cells 
showed little to none expression of this marker, according to the results found in the 
RNA studies. However, the majority of cells in all brain regions analyzed expressed the 
P2RY12 marker in their surface.  
 43 
 
This discordance between the results found by RNA analysis and by 
immunohistochemistry may have two main possible causes. On the one hand, it is 
possible that cells expressing this marker do so at the levels of adult cells, but that the 
populations of cells that do not express this marker are a sufficiently large percentage of 
the total population of eGFP
+
 cells that they produce this mismatch. However, from the 
imaging, this explanation does not seem to hold on its own, as the number of cells that 
are P2RY12
-
 is not large enough to induce these differences. What appears to be more 
likely is that although these postnatal cells are expressing the P2RY12 marker, they are 
doing so at levels that are lower than the levels of expression found in adult microglia.  
P2RY12 is a G protein-coupled purinergic receptor [72] which has been found to 
regulate microglial translocation [73], microglial closure of the injured blood–brain 
barrier [74] and microglial activation by extracellular nucleotides [75]. As all of these 
functions are more related to the role microglial cells have in the adult brain (sensing, 
immune cells), it may seem reasonable that this marker is more expressed in mature 
cells than it is during development, when microglial cells have more structural roles. 
From the results of the immunohistochemistry analysis, the microglial population 
at P3 can be described as being less numerous than at later stages, with a primitive 
ramified morphology and mostly expressing the microglial marker P2RY12. 
To sum up, the three objectives for this project were attained, and overall the 
results of this project provide a good general characterization of the microglial 
population at P3. The main conclusions and future lines of work can be found in section 
6.  
Legal framework 
This work involves animal research, and as such, it is subjected to the 
corresponding ethical and legal regulations. All animal procedures were approved by 
the local ethics committee. Animals were handled according to Real Decreto 53/2013 of 
Spanish law, which obliges with the EU Directive 2010/63/UE concerning the 
protection of animals used for scientific purposes. This research was done according to 
the last modification of this law presented on the Spanish BOE on the 20
th
 of 
November, 2018.  
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Besides, animal handling for experimental or other scientific purposes requires 
specific permits. In this regard, all animal handling performed during this project was 
done by certified personnel according to Order ECC/566/2015 from Spanish law.   
Socioeconomic impact 
24 million people worldwide are affected by Alzheimer and other dementias 
according to the World Health Organization [76], and this number is expected to grow 
as the population ages. There is currently no treatment for Alzheimer’s disease and 
other neurodegenerative diseases, in many cases, because the cause is unknown. 
Understanding the role microglial cells play in these diseases may unveil potential 
targets for treatment.  
This project will have no direct socioeconomic impact in this issue, as it has no 
direct application for any potential therapy or treatment for any of the diseases where 
microglial cells are involved. Nevertheless, this project helped support the thesis that 
current ways of modeling microglial cells should be revisited, and that gaining an 
understanding of microglial development should be a focus for the research field. If new 
protocols for obtaining microglial implement this approach, the models for microglial 
testing will be more significant, and thus the results more reliable. In the end, an easy, 
reliable model for microglial biochemical and drug testing would greatly enhance the 
research into diseases that affect the CNS, and provide great value to society.  
Budget 
The approximate costs of this project were calculated accounting for three different 
types of expenses: human resources, technical equipment and expendable laboratory 
materials, including reagents.  
Human resources  
The human resources costs account for the salaries of all the people working in this 
project and are detailed in Table II.  
Table II. Human resources costs 
Concept Hours Cost/hour Total cost  
Project 
supervisor 
100 35 3500€ 
Student 580 20 11600€ 
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Confocal 
scientist 
25 35 875€ 
Lab technicians 200 25 5000€ 
  Total 21000€ 
 
Technical equipment 
Technical equipment costs and software licenses costs were approximated based on 
the total cost of each equipment, its expected life and the months of use. The details of 
the technical costs are shown in Table III.  
Table III. Technical equipment costs 
Concept Expected life Cost Months used Total cost  
FlowJo 
License (with 
academic 
discount) 
5 years 2695 8 360€ 
GraphPad 
Prism 7 license 
1 year 
subscription 
150 8 100€ 
ImageJ  free 8 0€ 
Leica DM IL 
LED 
5 years 2750 8 367€ 
Other 
laboratory 
devices 
(centrifuge, 
shaker) 
5 years 5472+447 8 789€ 
Personal 
computer 
5 years 800 8 107€ 
   Total 1723€ 
 
Although the use of the confocal microscope is free of charge for ISCIII users, the 
estimate cost per use is 20€/hour, accounting to a total of 800€.  
Laboratory materials 
For general laboratory reagents (PBS, sucrose, ethanol, chloroform…) that are 
bought in bulk an estimate of the monthly budget is provided. For the cytokines, 
antibodies, cell culture reagents and qRT-PCR reagents, price was calculated based on 
the prices on the providers’ websites on the 27th of May, 2019. Expendable laboratory 
material (pipette tips, falcon tubes, cell culture flasks, etc.) was provided by Insituto de 
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Salud Carlos III. The estimate price for each order was around 30€, and they were done 
approximately monthly.  
Table IV. Laboratory materials costs 
Concept Units Cost per unit Total 
Cell culture reagents 2 200 400 € 
Cell culture cytokines 1 1140 1140€ 
qRT-PCR reagents 2 960 1920€ 
General laboratory 
reagents 
8 50 400€ 
FC antibodies 2 200 400€ 
Laboratory reagents    
IHC Primary 
antibodies 
2 400 800€ 
IHC Secondary 
antibodies 
2 200 400€ 
Expendable 
laboratory material 
8 30 240€ 
  Total costs 5700€ 
Total costs 
The final total cost of the project including all expenses was 27948 as shown in 
Table V.  
Table V. Total costs 
Concept Total cost  
Human resources 19725 
Technical equipment 1723 
Confocal microscope use 800 
Laboratory materials 5700 
Total 29198€ 
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6. Conclusions and future work 
Conclusions 
The main conclusions reached after ending this project are the following: 
1. Primary cultures of postnatal microglial (P3) cells stimulated with GM-CSF are 
not a good model for adult microglial studies, as they lack the expression profile found 
on adult microglial cells (FCRLS, P2RY12, TMEM119, TREM2).  
2. Neonatal microglia from P3 mice also show lower RNA expression levels than 
adult microglia for these markers due to their immature phenotype.  
3. Since neonatal microglia does not present the adult levels of microglia markers 
either, it cannot be said that cells obtained from postnatal primary cultures are not 
microglia, but rather that they come from immature microglia and are not differentiating 
in the in vitro cultures. 
4. This immature phenotype of microglial cells is also found in 
immunohistochemistry analysis of postnatal brains. As had been shown for other 
microglial models (using CX3CR1-eGFP transgenic mice, for example), microglia in 
postnatal day 3 present a primitive ramified morphology and are less numerous than at 
later stages.  
5. Most microglial cells at P3 express the purinergic receptor P2RY12, one of the 
main microglial markers.  
Future work 
From the conclusions reached above, the main takeaway moving forward is that in 
order to obtain primary postnatal microglial cultures that are reliable models for 
microglial function in the adult brain, the purpose of the cell cultures should not only be 
to amplify the number of cells, but also to guide their differentiation towards a more 
mature phenotype. In order to do so, the culture environment should include all the 
environmental cues that drive this development in vivo. This approach has proven 
successful in differentiating iPSC to microglia that resemble fetal microglia [43], [44], 
[66].  
Next steps in this work would be to culture postnatal microglial cells with 
cytokines that are involved in the development from neonatal to adult microglia, like M-
CSF, IL-34 and TGF-β1 and analyze whether they drive the immature cells towards a 
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more mature phenotype. A first approach towards this end, changing GM-CSF by M-
CSF in the Marshall et al. protocol tested in this project, seemed to yield promising 
results.  
However, the knowledge of the developmental process is uncomplete, and until 
there is a clear understanding of the in vivo process, attempts to replicate it in vitro will 
yield only partial results. So the main focus of any research in this area should be to 
characterize the microglial development, for example, by using transgenic models that 
are KO for different factors or receptors that are suspected of being involved.  
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